title: Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.
abstract: OBJECTIVE
  To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas.
  
  
  METHODS
  Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy.
  
  
  RESULTS
  Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18%±5%, and the estimated 1-year OS was 53%±6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension.
  
  
  CONCLUSIONS
  Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
authors.affiliation: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA. bradley@humonc.wisc.edu
authors.forename: Kristin A
authors.initials: KA
authors.lastname: Bradley
authors.forename: Tianni
authors.initials: T
authors.lastname: Zhou
authors.forename: Rene Y
authors.initials: RY
authors.lastname: McNall-Knapp
authors.forename: Regina I
authors.initials: RI
authors.lastname: Jakacki
authors.forename: Adam S
authors.initials: AS
authors.lastname: Levy
authors.forename: Gilbert
authors.initials: G
authors.lastname: Vezina
authors.forename: Ian F
authors.initials: IF
authors.lastname: Pollack
mesh_terms: D000293:Adolescent; D020295:Brain Stem Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005260:Female; D005910:Glioma / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007223:Infant; D007262:Infusions, Intravenous; D008099:Liver / Q000201:enzymology; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D008665:Metalloporphyrins / Q000009:adverse effects / Q000627:therapeutic use*; D011149:Pons; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D008665:Metalloporphyrins; D011838:Radiation-Sensitizing Agents; C437683:motexafin gadolinium